ENTA
ENANTA PHARMACEUTICALS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 23 Enanta Pharmaceuticals, Inc. v. Pfizer Inc.
- Aug 10 ▲ Enanta reported a narrower-than-expected net loss of $0.45 per share…
- Oct 29 ▼ The Unified Patent Court (UPC) of the European Union ruled that Enan…
- Nov 16 ▼ Earnings: ENTA Q4 2026 Earnings: EPS $-0.81 (-1.4% vs est)
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 11 added (0 new), 12 trimmed or exited.
- AnalystsBULLISH
11 of 12 rate it Buy or better.
- Short sellersCOVERING
Short interest −18.0% to 1.86M shares. 7.6 days to cover, ≈6.4% of shares.
- TrendDOWNTREND
10% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Qube Research & Technologies Ltd | ADD | $2.1M |
| Rockefeller Capital Management L.P. | TRIM | $1.1M |
| MARSHALL WACE, LLP | TRIM | $960.2K |
| ALPS ADVISORS INC | ADD | $505.0K |
| SEI INVESTMENTS CO | TRIM | $439.2K |
| UBS Group AG | TRIM | $384.1K |
| FRANKLIN TEMPLETON INC | TRIM | $374.5K |
| BARCLAYS PLC | ADD | $355.2K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
12 analysts| Date | Firm | Rating |
|---|---|---|
| Sep 23, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Jun 23, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Rottinghaus Scott T. Chief Medical Officer Aug 8, 2026 | TAX W/H | $19.6K |
Russell Lesley Director Mar 11, 2026 | AWARD | 20,000 sh |
CARTER BRUCE L A Director Mar 11, 2026 | AWARD | 20,000 sh |
Hata Yujiro S Director Mar 11, 2026 | AWARD | 20,000 sh |
Vance Terry Director Mar 11, 2026 | AWARD | 20,000 sh |
Peterson Kristine Director Mar 11, 2026 | AWARD | 20,000 sh |
FOLETTA MARK G Director Mar 11, 2026 | AWARD | 20,000 sh |
Kowalsky Matthew Paul Chief Legal Officer Feb 12, 2026 | TAX W/H | $27.1K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 1 bullish · 2 bearish · 1 mixed · 3 neutral- NEUTRAL SC 13GNov 16, 2026
ADAR1 Capital Management, LLC filed a new Schedule 13G disclosing a 6.0% passive stake in Enanta Pharmaceuticals as of September 30, 2026, representing 1,733,320 shares. The filing certifies passive intent with no plan to influence control.
🔒 Fresh report (last 24h), subscribers only
- BEARISH SC 13G/ANov 16, 2026
Farallon Capital Management filed an amended Schedule 13G disclosing a reduced passive stake of 3.3% (950,000 shares) in Enanta Pharmaceuticals as of September 30, 2026, down from a prior stake of 5.4% reported by BlackRock in October 2026. The reduction below the 5% threshold signals a potential…
🔒 Fresh report (last 24h), subscribers only
- MIXED INST-CLUSTERNov 9, 2026
Institutional activity in ENTA during Q3 2026 was mixed: two small asset managers added modest…
The selling is concentrated among three asset managers, with Russell Investments alone accounting for $988K of the $1.2M reduction. Without insider buying or a catalyst in the provided context, this…
- BEARISH 8-KOct 29, 2026
The Unified Patent Court (UPC) of the European Union ruled that Enanta's European Patent No. EP 4…
The invalidation of the patent eliminates a key catalyst for Enanta's valuation. Monitor whether Enanta files an appeal to the UPC Court of Appeal or pursues parallel litigation in individual EU…
All ENTA filing & press-release reports (7)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- INST-CLUSTER reportNov 9, 2026
- 8-K reportOct 29, 2026
- 8-K reportOct 28, 2026
- SC 13G reportOct 27, 2026
- 8-K reportAug 10, 2026